Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 23, 20 December 2023
Open
Access | Article
Vemurafenib treatment for melanoma: Efficacy, toxicity, and resistance
* Author to whom correspondence should be addressed.
Abstract
Melanoma is a malignant form of melanocytes, which has abnormal genetic alternation on the MAPK signalling pathway. Vemurafenib is a targeted therapy agent of melanoma, which is approved to target BRAF V600E-mutant melanoma in the US and EU. As an analogue of PLX4720, it has a promoted efficacy but maintain the selectivity to BRAF V600E kinase. Although vemurafenib has demonstrated its strong effects in clinical, potential toxicity of cutaneous lesions is a serious side effect problem in vemurafenib treatment. To avoid such serious adverse event, refrain from sun exposure and combination therapy with vemurafenib are suggested. Reactivation of the MAPK signalling pathway is the main acquired resistance of BRAF inhibitors, combinatorial therapies are suggested but with limited effects, new small molecules are undergoing development. DNA-based diagnostic test is a priority to determine gene types and detect BRAF mutations for patient stratification.
Keywords
melanoma, vemurafenib, BRAF, drug resistance, patient stratification
References
1. Sharma, A. et al., “Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies, ” Drugs (New York, N.Y.). 72 (17), 2207–2222 (2013)
2. Sandru, A. et al., “Survival rates of patients with metastatic malignant melanoma.” Journal of medicine and life, 7 (4), 572–576 (2014)
3. Domingues, B. et al., “Melanoma treatment in review, ” ImmunoTargets and therapy, 735–49 (2018)
4. Schadendorf, D. et al., “Melanoma, ” Nature reviews. Disease primers, 1 (1), 15003–15003 (2015)
5. Schadendorf, D. et al., “Melanoma, ” The Lancet (British edition), 392 (10151), 971–984. (2018)
6. Keating, G. M. and Lyseng-Williamson, K. A., “Vemurafenib: A Guide to its Use in Unresectable or Metastatic Melanoma”, American journal of clinical dermatology, 14 (1), 65–69 (2012)
7. Tsai, J. et al., “Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity”, Proceedings of the National Academy of Sciences – PNAS, 105 (8), 3041–3046 (2008)
8. HONG YANG et al., “RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models, ” Cancer research (Chicago, Ill.), 70 (13), 5518–5527. (2010)
9. Sala, E. et al., “BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells, ” Molecular cancer research. 6 (5), 751–759 (2008)
10. Chapman, P. B. et al., “Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, ” The New England journal of medicine, 364 (26), 2507–2516 (2011)
11. Kaley, T. et al., “BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study, ” Journal of clinical oncology, 36 (35), 3477–3484 (2018)
12. Flaherty, K. T. et al., “Inhibition of Mutated, Activated BRAF in Metastatic Melanoma”, The New England journal of medicine, 363 (9), 809–819 (2010)
13. Sosman, J. A. et al., “Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib, ” The New England journal of medicine, 366 (8), 707–714 (2012)
14. Martin-Liberal, J. and Larkin, J., “Vemurafenib for the treatment of BRAF mutant metastatic melanoma, ” Future oncology (London, England), 11 (4), 579–589 (2015)
15. Huang, V. et al., “Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway, ” Archives of dermatology (1960), 148 (5), 628–633. (2012)
16. Welsh, S. J. and Corrie, P. G., “Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma, ” Therapeutic Advances in Medical Oncology, 7 (2), 122–136 (2015)
17. Chen, P. et al., “Systematic review and meta‐analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma, ” Clinical and experimental dermatology, 44 (3), 243–251 (2019)
18. Russo, I. et al., “Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma, ” Scientifica (Cairo), 5(03), 6213–6217 (2018)
19. Reizner, G. T. et al., “Basal cell carcinoma and keratoacanthoma in Hawaiians: An incidence report, ” Journal of the American Academy of Dermatology, 29 (5), 780–782 (1993)
20. Dummer, R. et al., “Ultraviolet A and Photosensitivity during Vemurafenib Therapy, ” The New England journal of medicine, 366 (5), 480–481 (2012)
21. Manousaridis, I. et al., “Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management: Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK, ” Journal of the European Academy of Dermatology and Venereology, 27 (1), 11–18 (2013)
22. Manzano, J. L. et al., “Resistant mechanisms to BRAF inhibitors in melanoma, ” Annals of translational medicine, 4 (12), 237–237 (2016)
23. Molinari, F. & Frattini, M., “Functions and Regulation of the PTEN Gene in Colorectal Cancer, ” Frontiers in oncology, 3326–326 (2013)
24. Smalley, K. S. M. et al., “Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas, ” Molecular cancer therapeutics, 7 (9), 2876–2883 (2008)
25. Luebker, S. A. & Koepsell, S. A., “Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies, ” Frontiers in oncology, 9268–268 (2019)
26. Ascierto, P. A. et al., “Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, ” The lancet oncology, 17 (9), 1248–1260 (2016)
27. Tian, Y. & Guo, W. “A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma, ” Medical science monitor, 26e920957–e920957 (2020)
28. Anwar, M. A. F. et al., “Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature, ” The Journal of surgical research, 203 (2), 407–415 (2016)
29. Arozarena, I. & Wellbrock, C., “Overcoming resistance to BRAF inhibitors, ” Annals of translational medicine, 5 (19), 387–387 (2017)
30. Cheng, L. et al. “Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine, ” Modern pathology, 31 (1), 24–38 (2018)
31. Lopez-Rios, F. et al. “Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib, ” PloS one, 8 (1), e53733–e53733 (2013)
32. Jurkowska, M. et al., “Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes, ” International journal of clinical and experimental pathology, 8 (7), 8487–8493 (2015)
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-219-0
- ISBN (Online)
- 978-1-83558-220-6
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/23/20231008
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited